Get started
PFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05PFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05PFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05

PFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

PFE trade ideas

TARGET HIT $PFR 9.05% in 14 days TARGET HIT $PFR 9.05% in 14 days Wooo hoooo…. Great game!!! Definitely room for this to go higher... —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your own due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!! (\_/) ( •_•) / >🚀
NYSE:PFE
by SPYder_QQQueen_Trading
PFE Pfizer on the 8hr Popping the cloud.So I have been blending a lot of my styles together and recently i have had a lot of success with the 4 hr Chart using the cloud. When I remembered that I use to trade multiple timeframes because they repeat the same pattern on each time frame. So if that was the case I should be able to find a 8 hour chart where PFE is popping the cloud since the 4hr had already popped the cloud days ago. So I pulled up the 8hr and it was sitting in the cloud about to pop. It just popped the cloud and now is coming back down to find support before breaking out to go for a new high. Resistance is at 43.70. Once it gathers up enough shares to control the float it will clear this area. The white line is actually the copy of the same move on the 4hr chart. I copied and pasted it on the 8 hr so I can get the exact same path the 4hr took on the 8hr chart. by iCantw84it 11.01.2021
NYSE:PFELong
by iCantw84it
3
$PFE - Key Levels and Analysis$PFE - Key Levels and Analysis So it looks like It might be time to start a position in PFE… Target 45.92, or double position at 38.30 @Smartdaytrading I’m not sure if you saw this since the last post, its right at that projected buy level. This is definitely on my radar for tomorrow. —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!!
NYSE:PFELong
by SPYder_QQQueen_Trading
2
Pfizer could be a low risk play at this levels..!Pizer reacted to 200 EMA as well as one of the most important support levels(green line) and just gets out of the downward regression channel. I think it is highly likely we see higher prices in the coming days. My yesterday analysis: (it was not published publicly): Entry: 41.55 Stop loss:40.92 Reward/Risk:5.03 Target range: 44.55 Time Frame: 2Wks Possible gain: 7.635 Possible loss: 1.52% Position size: 5 % of trading capital This is a trade opportunity before the next earning call DISCLAIMER I’m not a certified financial planner/advisor nor a certified financial analyst nor an economist nor a CPA nor an accountant nor a lawyer. I’m not a finance professional through formal education. The contents on this site are for informational purposes only and do not constitute financial, accounting, or legal advice. I can’t promise that the information shared on my posts is appropriate for you or anyone else. By using this site, you agree to hold me harmless from any ramifications, financial or otherwise, that occur to you as a result of acting on information found on this site.
NYSE:PFELong
by Moshkelgosha
4
PFIZER INC: FUNDAMENTAL ANALYSIS REPORT+NEXT TARGET|MUST READ 🔔Late last month, Pfizer announced that its drug abrocitinib had been approved by Japan's Ministry of Health, Labor and Welfare (MHLW) as a treatment for patients aged 12 and older with moderate to severe atopic dermatitis or eczema. The Japanese approval of abrocitinib under the trade name Cibinqo came just weeks after the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved the drug for adults and adolescents with moderate to severe eczema. Let's take a look at why the MHLW approved the drug for use in eczema, as well as its sales potential and what it means for Pfizer. Typically, first-line therapy for eczema patients is topical corticosteroids (TCS), which are effective in treating most eczema patients. But for the large minority of eczema patients who do not experience significant benefits from TCS, there is a huge unmet medical need. And this is where Pfizer's Cibinqo can make a big difference in treating complex eczema cases. For context, the leading eczema drug is Dupixent, which was developed jointly by Regeneron and Sanofi. Dupixent is also approved as a complementary treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, bringing the drug's sales to more than $8 billion last year. And although Pfizer will release the full results of the drug's latest phase 3 trial later, Cibinqo was found to outperform Dupixent in all measures of efficacy. More patients who received 200 milligrams of Cibinqo once daily compared to 300 mg of Dupixent once every two weeks reported a four-point improvement in peak itch severity on the numeric rating scale in the second week of treatment compared to baseline levels before treatment. Simply put, the Peak Itch Digital Rating Scale is used by health care providers to measure the intensity of itching in patients with moderate to severe eczema. Although full study data have not yet been published, Cibinqo has demonstrated greater efficacy than Dupixent in reducing itching in patients with eczema in the second week of treatment. This should lead to an improvement in the quality of life of eczema patients. With a better understanding of Cibinqo's effectiveness in treating eczema, we can now explore the sales potential of this drug for Pfizer. Cibinqo's Phase 3 clinical trial showing higher efficacy compared to Dupixent is certainly an advantage. However, in the coming months, when Pfizer presents additional data, it will become clear how much of an efficacy advantage Cibinqo has over Dupixent. This is because last month the U.S. Food and Drug Administration (FDA) issued new warnings for Janus kinase inhibitors such as Cibinqo. This may encourage health care providers worldwide to exercise caution when prescribing Cibinqo in favor of Dupixent if the benefits are deemed to outweigh the risks compared to Dupixent. The encouraging news for Cibinqo is that, at first glance, the percentage of patients who discontinued Cibinqo was similar to those who discontinued Dupixent because of adverse events. There are approximately 105 million adults in Japan, and given that the prevalence of eczema among adults is estimated at 6.5%, there are 6.8 million adults with eczema. Since 23.3% of eczema cases in Japan are estimated to be moderate to severe, there are about 1.6 million adults with moderate to severe eczema. Of these 1.6 million, about 19% will not be able to control their symptoms with TCS alone. Thus, the real market of adult patients in Japan with moderate to severe eczema for Cibinqo is about 300,000. Cibinqo is expected to win 10% or 30,000 of these patients, which conservatively accounts for the remaining efficacy and safety issues of Cibinqo compared to the leader Dupixent. Since the Institute for Economic and Clinical Analysis estimates that the annual price in the United States is between $30,000 and $40,000, and prescriptions in Japan are on average 43% cheaper than in the United States, Cibinqo would have a net price of $10,000 per year. Thus, this eczema indication should generate about $300 million in annual revenue for Pfizer in Japan alone. Although this is a fraction of a percent compared to Pfizer's expected revenue of $78 billion to $80 billion this year, it is a good additional income for the company. Although Cibinqo looks like a promising new drug for Pfizer, the company is not idly waiting for results. While established drugs such as the COVID-19 Comirnaty vaccine and the Prevnar-13 pneumonia vaccine are generating significant revenue, Pfizer is working to discover, research, and commercialize the next line of breakthrough drugs. Pfizer, for example, recently increased its research and development spending from $3.8 billion in the first half of last year to $4.5 billion this year. While no guarantee increased R&D spending will lead to the discovery of more drugs and approvals, it's the best chance pharmaceutical stocks have at innovating and staying relevant. That's why Pfizer's dividend yield of 3.7% is safe for the foreseeable future and is the best choice in its sector for stable income.
NYSE:PFEShort
by FOREXN1
9
WHETHER 200-EMA WILL STOP THE PHIZEZ SLIDING MODE?The Pfizer Inc. Stock has been in a sliding mode since August when it hit its all-time high at $51.84 per share. However, the slide was stopped yesterday from strong support 200-period Exponential moving average and 38.2 Fibo level, which prevented the stock from drifting lower. Overall, the stock continues to trade below the downside line taken from the high of September 7th, which keeps the short-term outlook negative. However, in order to get confident on a trend continuation, the experts would like to see a dip below $41.50. A decisive break below that barrier would confirm a forthcoming lower low and may initially target the $38.15 per share hurdle, defined as a support by the 23.6 Fibo corrections. If investors are not willing to buy near that price, then the price could experience declines towards the $33.44 area, which acted as a temporary floor for the stock between October 2020 and March 2021. Looking at our short-term oscillators, we see that the RSI moved lower but ticked up from slightly above 30, while the MACD, already negative, has just fallen below its trigger line. Both indicators detect downside speed, which enhances the case for further declines in this stock. The move that could change the short-term picture to positive is the subsequent rebound from 200-EMA and 38.2 corrections and a break above $42.65. This will confirm the break above the pre-mentioned downside line and a forthcoming higher high. The bulls may get encouraged to push the action towards the high around $44.84 or the peak of September 07th, at $47.52. If they don’t stop there, we could see them aiming for the all-time high above $50.00. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carry a high-risk level. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and such sites. Furthermore, one understands that the company carries zero influence over transactions, needs, and trading signals. Therefore, it cannot be held liable nor guarantee any profits or losses.
NYSE:PFE
by legacyFXofficial